

11.18.10.00

CLAIMS

1. An ophthalmic solution with viscosity enhancing and detergent properties for contact lenses, comprising one or more physiologically acceptable viscosity enhancing agents in aqueous solution having a non-Newtonian rheological behaviour, and one or more physiologically acceptable non-ionic surfactants, wherein the viscosity enhancing agent is hyaluronic acid, or its salts with alkali or alkaline earth metals, and the non-ionic surfactant is poloxamer.

2. An ophthalmic solution according to claim 1, further comprising one or more tonicity adjusting agents.

3. An ophthalmic solution according to claim 1 or 2, further comprising one or more buffers.

4. An ophthalmic solution according to any one of the preceding claims, comprising from 0.005% to 0.50% in weight of sodium hyaluronate and from 0.010% to 2.0% in weight of poloxamer 407.

5. An ophthalmic solution according to claim 4, containing the following ingredients in the quantities shown (weight percentages):

sodium hyaluronate	0.005-0.50 %
poloxamer <del>407</del>	0.010-2.0 %
sodium chloride	0.10-0.90 %
dibasic sodium phosphate 12 H <sub>2</sub> O	0.010-0.10 %
phosphoric acid	q.s. to pH=7.3
bidistilled water	q.s. to 100 %

6. Use of an ophthalmic solution comprising one or more physiologically

N 18.10.00

acceptable viscosity enhancing agents having a non-Newtonian rheological behaviour in aqueous solution and one or more physiologically acceptable non-ionic surfactants for the production of an ophthalmic preparation for deterging contact lenses during their use, wherein the viscosity enhancing agent is hyaluronic acid, or its salts with alkali or alkaline earth metals, and the non-ionic surfactant is poloxamer.

7. Use according to claim 6, wherein said ophthalmic solution further contains one or more agents for the adjustment of tonicity and one or more buffers.

8. Use according to claim 6 or 7, wherein said ophthalmic solution contains sodium hyaluronate as viscosity enhancing agent.

9. Use according to claim 8, wherein said ophthalmic solution comprises from 0.005% to 0.50% in weight of sodium hyaluronate and from 0.010% to 2.0% in weight of poloxamer.

09975125002501  
10520525/2260